AstraZeneca, Amgen Report Positive Tezepelumab Study Results

(Alliance News) - AstraZeneca PLC and Amgen Inc on Friday said positive full results from the ...

Alliance News 26 February, 2021 | 2:27PM
Email Form

(Alliance News) - AstraZeneca PLC and Amgen Inc on Friday said positive full results from the Navigator phase III trial of tezepelumab showed a reduction in the annualised asthma exacerbation rate in severe, uncontrolled asthma patients.

Tezepelumab blocks the action of thymic stromal lymphopoietin, an epithelial cytokine that plays a key role across the spectrum of asthma inflammation.

The Cambridge, England-based biopharmaceutical company also said tezepelumab demonstrated statistically significant improvements in every key secondary endpoint compared to placebo.

"These are ground-breaking results for the many patients with severe asthma who continue to face debilitating symptoms despite receiving standard of care inhaled medicines and currently approved biologics," said Andrew Menzies-Gow, director of the Lung Division, Royal Brompton Hospital, London, and principal investigator of the Navigator phase III trial.

"Tezepelumab has the potential to transform treatment for a broad population of patients with severe asthma regardless of their type of inflammation, including those with and without an eosinophilic phenotype," added Menzies-Gow.

Astra shares were trading 0.3% lower in London on Friday afternoon at 6,989.00 pence each. Amgen was up 0.6% to USD228.89 in the New York pre-market.

By Evelina Grecenko;

Copyright 2021 Alliance News Limited. All Rights Reserved.

Email Form

Securities Mentioned in Article

Security Name Price Change (%) Morningstar
AstraZeneca PLC 7,287.00 GBX 0.61
Amgen Inc 248.95 USD 0.84

About Author

Alliance News

Alliance News provides Morningstar with continuously updating coverage of news affecting listed companies.

Audience Confirmation

By clicking 'accept' I acknowledge that this website uses cookies and other technologies to tailor my experience and understand how I and other visitors use our site. See 'Cookie Consent' for more detail.

  • Other Morningstar Websites
© Copyright 2021 Morningstar, Inc. All rights reserved.

Terms of Use        Privacy Policy        Cookies       Modern Slavery Statement